Study to Evaluate the Safety of Twice Daily Oral Carvedilol
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the long-term safety of carvedilol in pediatric
patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321.
Carvedilol will be provided as open-label therapy for a period of at least 6 months (or until
termination of the study) by SmithKline Beecham Corporation d/b/a GlaxoSmithKline (GSK) or
the University Sponsor.